-
In knee OA, arthroscopic surgery confers no benefit.
-
Whereas racial concordance is the primary predictor of perceived ethnic similarity, patients do value higher communication skills, which may actually result in better outcomes.
-
The FDA has approved the first drug for the treatment of Huntington's disease.
-
Strategies to determine treatment of acute coronary syndromes need to take gender into account.
-
Lifestyle changes plus red yeast rice and fish oil resulted in similar beneficial effects on LDL cholesterol as moderate-dose statin therapy in patients meeting criteria for drug therapy for high LDL cholesterol.
-
Optimizing medical and lifestyle change therapy rather than performing PCI is appropriate as the initial management strategy for most patients with known CAD who do not have unstable or disabling symptoms.
-
A randomized controlled trial in the Netherlands showed that oral prednisolone and naproxen were equivalent in the treatment of acute gout with no difference in side effects.
-
Using blood pressure, BUN, serum sodium, and presence of peripheral arterial disease as predictors of mortality in heart failure patients, 67% who had 3 or more factors died within 6 months and would qualify for the Medicare hospice benefit.
-
There are no disease-modifying pharmacotherapies for COPD. That is, although bronchodilators, anticholinergic agents, and inhaled corticosteroids improve FEV1 and reduce symptoms, decline in pulmonary function continues unabated and lung function returns promptly to pretreatment status once medication is stopped.
-
Whereas its potential benefits remain uncertain, prostate-specific antigen (PSA) screening may be associated with psychological harms. There has been a recent update to the screening guidelines by the U.S. Preventive Services Task Force (USPSTF).
